¦³¾÷ÁC¤Î®ò°ò¥Ò»ÄÆQ±þÂξ¯¹AÃĤ¤¬r
(Organophosphate and Carbamate Poisoning)
³ø§i¡GÁ©s¦ëÂå®v; «ü¾É¡GªLªN¼Ù±Ð±Â
¤@¡BPhysostigmine¦b¦è«D³Qµo²{©ó1840¦~º«×³Q±a©¹^°ê
¤G¡B1877¦~ Laqueur
º¦¸¨Ï¥Î¥¦¨ÓªvÀø«C¥ú²´
¤T¡B1920¦~¥N
Neostigmine ¥Î¨ÓªvÀø«¯g¦ÙµL¤O
¥|¡B¤§«á¡Aparathion Åܦ¨¼sªx¨Ï¥Îªº±þÂξ¯
¤¡B1950¦~¥N
Carbamates ³Q¦X¦¨
¤@¡BºC©Ê¼ÉÅS¡G¹A·~¤Wªº¤j¶q¨Ï¥Î
¤G¡B¶W¹L250ºØªº«~µP¦b¬ü°ê¤W¥«¨Ï¥Î¡A¨ä¤¤ªº¦Ê¤À¤§¤K¤Q¬Ò¦³¤¤¬r¦í°|ªº³ø§i
¤T¡B¤p«Ä»~¹¡G«O¦s¤£·í¤Î©ö©ó¨ú±o
¥|¡B¦Û±þ·N¹Ï¡G©ö©óÁʱo¥BµLÄY®æ¥ßªk³W½d¡A¦³³ø§i«ü¥X¡A¤@¨Ç«D¬w°ê®aÄY«¤¤¬rªº®×¨Ò¤¤¡A¦³¦Ê¤À¤§¥|¤Q¦Ü¦Ê¤À¤§¤»¤Q¬OÄÝ©ó¦¹Ãþ, ¬°¥@¬É¤W³Ì±`¨£ªº¤¤¬r¤§¤@¡C
Acetylcholine
as a Neurotransmitter(¯«¸g¶Ç¾Éª«½è)¡G
¤@¡B°Æ¥æ·P¯«¸g¸`«á¯«¸g¤¸
¤G¡B¥æ·P¤Î°Æ¥æ·P¯«¸g¸`«e¯«¸g¤¸
¤T¡B°©¯Þ¦Ù¦Ù¦×¯«¸g¥æ±µ³B
¥|¡B¤¤¼Ï¯«¸g¨t²Î
- ¥¿±`¥Í²z±¡ªp¤U¡AAcetylcholine(Ach)·|³QAcetylcholinesterase(AchE)(»Ã¯À)¤ô¸Ñ¦¨Acetic acid¤ÎCholine
- ¨Å餺¦³¤GºØAchE¡A¦b¬õ¦å²y¤WªººÙ¬°True cholinesterase¡A¦b¦å²M¤¤ªººÙ¬°Pseudocholinesterase
¤@¡B¤Wz¨âºØ»Ã¯À¬Ò¥i»P¦³¾÷ÁCµ²¦X
¤G¡B¦³¾÷ÁC»PAchE§Î¦¨¦@»ùµ²¦X¡A¨ÏAch¤£³Q¤ô¸Ñ¡A³y¦¨overactivity
¤T¡BCarbamate»PAchEªºµ²¦X«h¬O¥i°f©Êªº
§@¥Îªº³¡¦ì
Muscarinic Symptoms¡G
©I§l¨t²Î¡G¯Ý´e¡B®ð«P¡B¤Àªc¼W¥[¡BªÍ¤ô¸~
¸zG¨t²Î¡Gäú¤ß¡B¹Ã¦R¡B¸¡µh¡B¸¡Âm¡BùØ«æ«á«¡B¥¢¸T
¤ß¦åºÞ¨t²Î¡G¤ß³Õ¹L½w¡B¦åÀ£¤U°
Muscarinic Symptoms ¡G
¥~¤Àªc¸¢¡G¬y¦½¡B¬y²\¡B¬y¤f¤ô
ªc§¿¨t²Î¡GÀW§¿¡B¤p«K¥¢¸T
²´·ú¡GÀû¤ÕÁY¤p¡Bµø¤O¼Ò½k¡BÀYµh
Nicotinic Manifestation ¡G
¤ß¦åºÞ¨t²Î¡G»a¥Õ¡B¤ß³Õ¹L³t¡B¦åÀ£¤W¤É
¾î¯¾¦Ù¡G¦Ù¦×Ÿ°Ê¡B©âÝz¡BµL¤O¡B³Â·ô
µJ¼{¡B¤£¦w¡B±¡ºü¤£©w¡B¥¢¯v¡B¦h¹Ú¡B°hÁY¡Bªq³à¡B¶ÝºÎ¡B·NÃѤ£²M¡Bataxia
¡B©ü°g¡BCheyne-Stokes ©I§l¡Bconvulsion ¡B©I§l¤¤¼Ï¤Î´`Àô¤¤¼Ï§í¨î
¶EÂ_ªºcriteria¡G¤U¦C¤T¶µªººî¦X
¤@¡BÁ{§É¼xÔªí²{
¤G¡B¦å²M¤¤»Ã¯À(AchE)¼Æ¥Ø´î¤Ö
¤T¡B¹ï©óAnticholinergicÃĪ«ªºªvÀø¦³¤ÏÀ³
¤TÓ¥Dnªºcriteria¡G
¤@¡B»Ý¤£»Ýn¨Ï¥Î¤H¤u©I§l¾¹
¤G¡B¦³µL¨Öµo¯g
¤T¡B¦í¦b¥[Å@¯f©Ðªº®É¶¡
µ²½×¡G»Poutcome³Ì¦³¬ÛÃöªº¦]¤l¢w
§]¹¶qªº¦h¹è
¹w«áªºµû¦ô¡G»OÆWªø©°¦Û¤vªº¬ã¨s
°ò©ó¦å²M¤¤»Ã¯À(Rseudocholinesterase)ªº´î¤Ö¨Ó§@grading¡G
µ²ªG¡Gªì©l»Ã¯À´î¤Öµ{«×¦b»´¦Ü¤¤«×ªÌ
¨ä¤¤20% ==> µo¥Í©I§l°IºÜ
28% ==> ¬ðµo¤ß¦åºÞ¶ò³´(collapse)
18% ==> ³Ì«á¦º¤`
µ²½×¡Gunworkable¡I
¥t¤@¶µ¬ã¨s
¥H³Ìªìªº¤ß¹q¹Ï¤§QTc©µªø§@¬°¹w«á¤£¦nPoor prognostic ªº«ü¼Ð
indicator¡G©w¸qQTc¤j©ó 0.440¬í¬°QTc prolongation
( Bazett¡¦s formula¡GQTc = QT/
(RR) )
»´«×(mild) ==> ¼ÉÅS©Î»~¹¯f¥v¡B·NÃÑ¥¿±`¡B
¤Ö¶q¤Àªc¼W¥[¡B»´·L©âÝz
««×(severe) ==> ¼ÉÅS©Î»~¹¯f¥v¡B·NÃѧïÅÜ¡B
¦h¶q¤Àªc¼W¥[¡BÄY«©âÝz
·¥««×(life-threating) ==> ¦Û±þ·N¹Ï¡B
·NÃÑ¡G¤ì»ø(stupor)
¡B
¦å®ñ°Ê¯ß¤ÀÀ£
< 75²@¦Ì¨E¬W¡B
¯Ý³¡X¥ú²§±`
¤@¡B¦]·|¸g¥Ñ¥Ö½§§l¦¬¡A¬G»Ý¨³³t¨R¬~¡A¥HªÎ¨m¥þ¨¬~¾þ(¥]¬AÀY¾v); ÂåÅ@¤Hû¶·À¹¤f¸n¤Î¤â¹Ü¡A¥H¨¾¤¤¬r¡C
¤G¡B«OÅ@©I§l¹D¡G©â§l¤Àªcª«
¤T¡B·NÃѤ£²M¤§¯f¤H¶·´¡ºÞ
¥|¡BºÊ´ú©I§l¥\¯à¡A§@°Ê¯ß¦å¤ÀªR
¤¡Bµ¹¤©§ÜÁxÆP(Anticholinergic)ÃĪ«
Atropine(ªü¦«¥)
¤@¡B¥i³q¹L¦å¸£»Ù½ª(Blood-Brain Barrier)¡A
·|¦³¤¤¼Ï¯«¸gªº°Æ§@¥Î¦p·NÃѲV²c¡B©ü°g¡BPsychosisµ¥
¤G¡B¾A·íªºatropinization¡G¤Àªcª«ªº¦h¹è
¤T¡B³sÄòºwª`V.S.«ÂЪ`®g(repeated bolus)
PAM¡G
¦A¬¡¤Æ(Reactive)»Ã¯À(AchE)¡AÂǵ۲¾°£¤Æ¦Xª«¤¤ªº¦³¾÷ÁC®Ú
¯S©Ê¡G¹ïparathion¡Bmevinphos ¡BDiazinon¸û¦³®Ä
°Æ§@¥Î¡G¥NÁ²£ª«(¦phydrogen
cyanide)¨ã¦³¬r©Ê¡A
·|¦³äú¤ß¡BÀY·w¡B·NÃѤ£²Mªº¯gª¬¡A¤£
©ö»P¦³¾÷ÁC¤¤¬r°Ï¤Àªº¯gª¬
PAM¡G
¤@¡B¤¤¬rªº¤»¤p®É¤º§ë»P³Ì¦³®Ä
¤G¡B¤G¤Q¥|¤p®É¤º§ë¬Ò¦³®Ä
¤T¡B·sÆ[©À¡Gªø´Á¨Ï¥Î¦³®Äªº°§C¤F¦Ù¦×¯fÅÜ(Acute Myopathy)
Glycopyrrolate
¤@¡B¥|¯ÅÓi¡A¤£·|¸g¹L¦å¸£»Ù½ª
¤G¡BÂùª¼¹êÅçÃÒ¹ê¡A»Patropine¤@¼Ë¦³®Ä
¤T¡B¸û¤Öªº©I§l¹D·P¬V²v
¥|¡B©|»Ý¤j³W¼Òªº¬ã¨s
¦´Á¦º¤`(¤G¤Q¥|¤p®É¤º)
¤@¡B¤¤¼Ï¯«¸g§í¨î
¤G¡B¤ß«Ç¤ß«ß¤£¾ã(¨Ò¦p¡GTorsade des points)
¤T¡B©I§l°IºÜ
±ß´Á¦º¤`
¤@¡B©I§l°IºÜ
¤G¡B·P¬V, ªÍª¢
¤T¡B¨Ï¥Î©I§l¾¹¤Î¥[Å@¯f©Ð·ÓÅU®É¬ÛÃöªº¦X¨Ö¯g
¤@¡B«æ©Ê¦Ù¦×¯fÅÜ
1. ¾î»J½¤
2. ì¦]¡GM¥~¶tÂ÷¤l¤j¶q¬y¤J²ÓM
3. ¦ÙÅÖºû°h¤Æ
¤G¡B¤¤¼Ï¯«¸g¨t²Î
1. ·NÃѼҽk
2. Medulla ªº¥Í©R¤¤¼Ï¨ü¨ì§í¨î
3. Åöíw
¤¤¶¡¯gÔ¸s(Intermediate Syndrome)
¦b¤j·ÀªQ¡B³³´µªQ¤¤¬r¯f±w®e©öµo¥Í, ¬ù¦b¤¤¬r¤G¡ã¤T¤Ñµo§@¡C
¤@¡B¬ðµo©Ê©I§l°IºÜ
¤G¡B¸£¯«¸g¨ü·l
¤T¡BÀV³¡¦ù¦Ù»P¤WªÏªñºÝ¦Ù¦×µL¤O
«ì´_¡G¦³¯S©w¶¶§Ç¡I
¤@¡B¸£¯«¸g³Â·ô³Ì¥ý«ì´_¡GÃE¯«¸g¡BÃC±¯«¸g¤Î²´¯«¸g (external ocular)
¤G¡B©I§l¾÷¯à»PªñºÝ¦Ù¦×¤O¶qªº«ì´_¦¸¤§
¤T¡BÀV¦ù¦Ù¡G³Ì±ß«ì´_
©I§l°IºÜ
¤@¡Bµo¥Í²v¡G«æ©Ê¦³¾÷ÁC¤¤¬rªº¯f¤H
°ª¹F40%
¤G¡BP¯f¦]¡G¦h«¦]¤l
1. Muscarinic¡G©I§l¹D¤Àªcª«¹L¦h
2. Nicotinic¡G©I§l¦ÙµL¤O
3. ¤¤¼Ï ¯«¸g¨t²Î¡G¸£·F¨ü§í¨î
±ß´Á¯«¸g¯fÅÜ(Delay Neuropathy)
¦b¸ûÄY«¦³¾÷ÁC¤¤¬r¦p¬ü¤åªQ¡B¹F°¨ªQ¡B¥Ò°ò¤Ú©ÔªQªº¯f±w®e©öµo¥Í
¤@¡B¥Dn¬O«I¥Ç¶gÃ䯫¸g¡Aµo¥Íªº®É¶¡¡G
³q±`¤j©ó¤@¶g
¤G¡B¤UªÏªº¦Ù¦×¯kµh
¤T¡Bº¥¶i©ÊªºµL¤O¤Î²`¸x¤ÏÀ³°§C
¥|¡B·Pı¥\¯à¡G³q±`¼vÅT«Ü¤p
¤¡BÀ@Åé¥~¯gÔ(Pyramidal Sign)
«ì´_
¤@¡B¥\¯à©Êªº«ì´_n¦b¤@¦~¥H«á
¤G¡BÄY«ªºcase¡G«ùÄò©Êªºspastic¤W¹B°Ê¯«
¸g¤¸¯gÔ¸s
¤T¡B¯«¸g¯f²z¾Çªº°²³]¡G¡y¤Æ¾Ç©ÊºIÂ_¡z(Chemical
Transsection)
¥|¡B°O¾Ð¤O»Ùê¡B²V²c¡Bļ°Ê¤£¦w¡B¶ÝºÎ»Pºë¯«¯f
¤¡B¤@¯ë¥u¬O¼È®É
Ãö©ó¦³¾÷ÁC¤¤¬rªºªvÀø¡A¨ä§V¤Oªº¤è¦V¡G
¤@¡B¥¿½Tªº¶EÂ_»P¦´Á¿n·¥ªºªvÀø
¤G¡BÄY««×ªºµû¦ô
¤T¡B¿n·¥ªº¥[Å@ªvÀø
¥|¡B¹ï©ó¦³¾÷ÁC¹AÃijc°âªººÞ¨î
°Ñ¦Ò¸ê®Æ
1. O'Malley M: Clinical enaluation of pepticide
exposure and poisoning. Lancet
1997 : 349:1161-66.
2. Bardine PG et al: Organophosphate and carbamate
poisoning: Arch Int Med 1994; 154: 1433-41.
3. De Bleecker JL et al: Neurological aspects of
organophosphate poisoning. Clin Neurol Neuosuger 1992; 94: 93-103.
4.
Chuang FR, Jang SW,
Lin JL et al: QTc prolongation indicates a poor prognosis in patients with
organophosphate poisoning. Am J Emerg Med 1996; 14:451-453.
¡@